In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study

In Burkitt lymphoma patients who relapse after induction with a short-intensive... Ann Hematol (2017) 96:1573–1575 DOI 10.1007/s00277-017-3044-4 LETTER TO THE EDITOR In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study 1 1 2 Martin Cremer & Mark-Alexander Schwarzbich & Tilman Schöning & 1 1 1 Katharina Lisenko & Anthony D. Ho & Mathias Witzens-Harig Received: 29 January 2017 /Accepted: 4 June 2017 /Published online: 16 June 2017 Springer-Verlag GmbH Germany 2017 Dear Editor, Therefore, we retrospectively analyzed the electronic Burkitt lymphoma (BL) is a highly aggressive non-hodgkin records of all patients (n = 38) who were newly diagnosed lymphoma (NHL) representing about 1% of mature NHLs [1]. with Burkitt lymphoma, Burkitt-like lymphoma, B-cell The German Multicenter Study Group for Adult ALL con- lymphoma unclassifiable with features intermediate be- ducted the multicenter GMALL-B-ALL/NHL2002 trial, tween DLBCL, and Burkitt lymphoma (BCLU) or which used a short-intensive protocol based on rituximab, Burkitt leukemia between 2003 and 2013 in our institu- high-dose methotrexate, and triple intrathecal therapy, with a tion and were treated with curative intent. Patients were reduced regimen for patients >55 years old. This trial reported enrolled in the GMALL-B-ALL/NHL2002 trial if eligible an 88% complete response (CR) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study

Loading next page...
 
/lp/springer_journal/in-burkitt-lymphoma-patients-who-relapse-after-induction-with-a-short-sP108tMY8o
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany
Subject
Medicine & Public Health; Hematology; Oncology
ISSN
0939-5555
eISSN
1432-0584
D.O.I.
10.1007/s00277-017-3044-4
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial